| Knowledge4COVID-19

Property	Value
is ?:annotates of	<https://research.tib.eu/covid-19/entity/32480420_HAS_TOPIC_C0003451> <https://research.tib.eu/covid-19/entity/32480420_HAS_TOPIC_C0005525> <https://research.tib.eu/covid-19/entity/32480420_HAS_TOPIC_C0009885> <https://research.tib.eu/covid-19/entity/32480420_HAS_TOPIC_C0018748> <https://research.tib.eu/covid-19/entity/32480420_HAS_TOPIC_C0021054> <https://research.tib.eu/covid-19/entity/32480420_HAS_TOPIC_C0032310> <https://research.tib.eu/covid-19/entity/32480420_HAS_TOPIC_C0033328> <https://research.tib.eu/covid-19/entity/32480420_HAS_TOPIC_C0086418> <https://research.tib.eu/covid-19/entity/32480420_HAS_TOPIC_C0206750> <https://research.tib.eu/covid-19/entity/32480420_HAS_TOPIC_C0268381> <https://research.tib.eu/covid-19/entity/32480420_HAS_TOPIC_C1527392> <https://research.tib.eu/covid-19/entity/32480420_HAS_TOPIC_C1615608> <https://research.tib.eu/covid-19/entity/32480420_HAS_TOPIC_C3494184> <https://research.tib.eu/covid-19/entity/32480420_HAS_TOPIC_C3694279> <https://research.tib.eu/covid-19/entity/32480420_HAS_TOPIC_C5203670> <https://research.tib.eu/covid-19/entity/32480420_HAS_TOPIC_C5203676> <https://research.tib.eu/covid-19/entity/32480420_HAS_TOPIC_C5241303> <https://research.tib.eu/covid-19/entity/32480420_HAS_TOPIC_C5243474> <https://research.tib.eu/covid-19/entity/32480420_HAS_TOPIC_C5392141>
?:authorAffiliation	[\'Plasma Cell Dyscrasia Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.\', \'National Amyloidosis Centre, London, UK.\', \'Medical Department V, Amyloidosis Centre, University Hospital Heidelberg, Heidelberg, Germany.\', \'Amyloidosis Center, School of Medicine and Boston Medical Center, Boston University, Boston, MA, USA.\', \'Department of Molecular Medicine, Amyloidosis Research and Treatment Center, Foundation \'Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo\', University of Pavia, Pavia, Italy.\', \'Department of Hematology, UMC Utrecht Cancer Center, Utrecht, The Netherlands.\', \'Clinical Hematology, IUC Oncopole/CHU Toulouse, Toulouse, France.\', \'CHU Poitiers, Poitiers, France.\', \'Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.\', \'Hematology Department, Amyloidosis and Myeloma Unit, Hospital Clínic of Barcelona, University of Barcelona, IDIBAPS, Barcelona, Spain.\']
?:citedBy	-1
?:creator	<https://research.tib.eu/covid-19/entity/Blade_Joan> <https://research.tib.eu/covid-19/entity/Cibeira_Maria_T> <https://research.tib.eu/covid-19/entity/Dimopoulos_Meletios_A> <https://research.tib.eu/covid-19/entity/Hegenbart_Ute> <https://research.tib.eu/covid-19/entity/Jaccard_Arnaud> <https://research.tib.eu/covid-19/entity/Kastritis_Efstathios> <https://research.tib.eu/covid-19/entity/Kumar_Shaji> <https://research.tib.eu/covid-19/entity/Merlini_Giampaolo> <https://research.tib.eu/covid-19/entity/Minnema_Monique> <https://research.tib.eu/covid-19/entity/Palladini_Giovanni> <https://research.tib.eu/covid-19/entity/Roussel_Murielle> <https://research.tib.eu/covid-19/entity/Sanchorawala_Vaishali> <https://research.tib.eu/covid-19/entity/Sch%C3%B6nland_Stefan> <https://research.tib.eu/covid-19/entity/Wechalekar_Ashutosh>
?:doi	10.1111/bjh.16898
?:doi	<https://research.tib.eu/covid-19/entity/10.1111/bjh.16898>
?:hasPublicationType	<https://research.tib.eu/covid-19/entity/Journal_Article> <https://research.tib.eu/covid-19/entity/Review>
?:journal	British journal of haematology
is ?:pmid of	<https://research.tib.eu/covid-19/entity/32480420>
?:pmid	<https://research.tib.eu/covid-19/entity/32480420>
?:pmid	32480420
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/Covid-19>
?:rankingScore_SJR	2.036
?:rankingScore_hIndex	169
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/C0268381_COEXISTS_WITH_C3277906> <https://research.tib.eu/covid-19/entity/C0268381_PROCESS_OF_C0030705> <https://research.tib.eu/covid-19/entity/C0422837_PROCESS_OF_C0030705> <https://research.tib.eu/covid-19/entity/C0678236_PROCESS_OF_C0030705>
?:title	Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic.
?:type	<https://research.tib.eu/covid-19/vocab/Publication> <https://research.tib.eu/covid-19/vocab/Publication_Author>
?:year	2020

Property

Value

is ?:annotates of

?:authorAffiliation

[\'Plasma Cell Dyscrasia Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.\', \'National Amyloidosis Centre, London, UK.\', \'Medical Department V, Amyloidosis Centre, University Hospital Heidelberg, Heidelberg, Germany.\', \'Amyloidosis Center, School of Medicine and Boston Medical Center, Boston University, Boston, MA, USA.\', \'Department of Molecular Medicine, Amyloidosis Research and Treatment Center, Foundation \'Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo\', University of Pavia, Pavia, Italy.\', \'Department of Hematology, UMC Utrecht Cancer Center, Utrecht, The Netherlands.\', \'Clinical Hematology, IUC Oncopole/CHU Toulouse, Toulouse, France.\', \'CHU Poitiers, Poitiers, France.\', \'Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.\', \'Hematology Department, Amyloidosis and Myeloma Unit, Hospital Clínic of Barcelona, University of Barcelona, IDIBAPS, Barcelona, Spain.\']

?:citedBy